Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226965 · ClinicalTrials.gov registry record · Phase 2
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
A Phase 2 study of Lymphoma, Diffuse Large B-Cell, sponsored by Sierra Oncology LLC - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT02226965 is a Phase 2 study of Lymphoma, Diffuse Large B-Cell that has completed, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 45 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT02226965, a Phase 2 study of Lymphoma, Diffuse Large B-Cell, has completed, sponsored by Sierra Oncology LLC - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma.
Conditions Studied
Interventions
- DRUG PNT2258
Study Locations (20)
Michigan
- Mercy Health Saint Mary's - Grand Rapids
- St. John Hospital and Medical Center - Grosse Pointe Woods
- Michigan State University - Lansing
- William Beaumont Hospital - Royal Oak
California
- Long Beach Memorial Medical Center - Long Beach
- University of Southern California - Los Angeles
Florida
- Lynn Cancer Institute - Boca Raton
- Bond Clinic, P.A. - Winter Haven
Colorado
- Colorado Blood and Cancer Institute - Denver
Georgia
- Georgia Regents University - Augusta
Illinois
- Rush University Medical Center - Chicago
Indiana
- Horizon Oncology Research, Inc. - Lafayette
Louisiana
- UHC Oncology - Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02226965
The ClinicalTrials.gov registry entry for NCT02226965 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sierra Oncology LLC - a GSK company, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma, Diffuse Large B-Cell appearing as the primary indexed condition, and to 1 intervention - of which PNT2258 is the first listed.
NCT02226965 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Michigan, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02226965 about?
NCT02226965 is a clinical study titled "PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)". This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory (r/r) diffuse large B-cell lympho...
What is the current status of trial NCT02226965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2014-12. Estimated completion is 2018-08-22.
What conditions does trial NCT02226965 study?
This clinical trial studies the following conditions: Lymphoma, Diffuse Large B-Cell.
What interventions are being tested in trial NCT02226965?
The interventions under investigation include: PNT2258 (DRUG).
Who is sponsoring clinical trial NCT02226965?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02226965 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.